Topics

Glioblastoma | Diagnosis | Magnetic resonance imaging | Differentiation Progression-Pseudoprogression and Progression-Necrosis

Home > Publications > Topics > Glioblastoma > Diagnosis > Magnetic resonance imaging > Differentiation Progression-Pseudoprogression

Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis

Khalaj K, Jacobs MA, Zhu JJ, Esquenazi Y, Hsu S, Tandon N, Akhbardeh A, Zhang X, Riascos R, Kamali A.
The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.
Cancers (Basel). 2024 Jul 2;16(13):2440. doi: 10.3390/cancers16132440. PMID: 39001500. Observational study. ˍ

Differentiation between progression and pseudoprogression

van Dorth D, Croese RJI, Jiang FY, Schmitz-Abecassis B, Taphoorn MJB, Smits M, Dirven L, van Osch MJP, de Bresser J, Koekkoek JAF.
Perfusion MRI-based differentiation between early tumor progression and pseudoprogression in glioblastoma and its use in clinical practice.
Neurooncol Pract. 2024 Oct 15;12(2):281-290. doi: 10.1093/nop/npae099. PMID: 40110054. Observational study. ˍ

Var V, Leu SM, Rommers N, Psychogios MN, Cordier D, Todea RA.
Differentiation of tumor progression from pseudoprogression in glioblastoma patients with GRASP DCE-MRI and DSC-MRI.
J Neuroradiol. 2025 May 24;52(4):101354. doi: 10.1016/j.neurad.2025.101354. PMID: 40419180. Observational study. ˍ